Home · Medication guides
Step therapy

Biologics denied: Humira, Enbrel and the TNF inhibitors

TNF inhibitor denials usually come from a step therapy rule that asks you to fail a cheaper drug first. Here is what the rule requires, what an exception has to show, and what to gather before you appeal.

HumiraEnbrelRemicadeCimziaSimponiadalimumabetanerceptinfliximabadalimumab biosimilars
Cove Health·

Denials of TNF inhibitors are rarely a judgment that the drug is wrong for you. They are usually a plan rule firing: a step therapy protocol that requires a cheaper drug first, or a prior authorization policy whose criteria the submitted paperwork did not visibly meet. Both are answered with documentation rather than argument, which is why what sits in your chart matters more here than almost anywhere else.

Why was my biologic denied?

Step therapy. Most plans cover biologics for inflammatory conditions only after conventional therapy has been tried. In rheumatoid arthritis that is commonly methotrexate or another conventional agent; in psoriasis it may be phototherapy or a systemic drug; in inflammatory bowel disease it may be a different class again. If the record does not show the required step, at an adequate dose and for an adequate duration, the claim is denied even when the trial happened.

Prior authorization criteria. Policies for this class typically ask for the diagnosis and how it was established, a measure of disease activity, and evidence of screening the label calls for. A request that omits any of these is denied as criteria not met.

Product preference within the class. Plans preference specific products, including biosimilars, and require an exception to cover a non-preferred one. This is a purchasing decision made at the formulary level, not a statement about your case.

Site of care or billing route. Infused products can be denied not on the drug but on where it is given, when the plan requires a lower-cost setting. That denial is about the site, and it is answered separately from the drug itself.

What does the denial letter actually mean?

The notice should name the rule it applied. "Step therapy required" means the plan wants a documented trial of something it names first. "Criteria not met" means the policy exists, the drug is covered, and the submission did not establish a point the policy asks for, which is usually recoverable. "Non-preferred product" points at a formulary exception rather than a clinical dispute. "Not medically necessary" is the plan's reviewer concluding the written criteria were not satisfied by partial records, and it is answered on the medical necessity route.

Whichever phrase appears, the notice must tell you the appeal deadline and the address. Those two lines are the ones to find first.

What can I do in the next 48 hours?

Our general guide covers the first 48 hours after a denial. For a biologic, the specific work is building a treatment history a stranger can verify.

Ask your plan in writing for the step protocol or coverage policy it applied. Ask your prescriber's office for the notes that record each prior drug: name, start and stop dates, dose and titration, and what happened, in clinical terms rather than recollection. Pharmacy fill records are often the cleanest evidence that a trial actually happened, particularly for a drug tried years ago or under a different insurer. Where a drug was stopped for a side effect, find the note or visit where the reaction was reported.

If you are unsure whether you are facing a step rule, an exception, or a necessity denial, the free denial check sorts it out in about a minute, with no account.

How does a physician-written appeal help for biologics?

These cases are won or lost on the record, and assembling that record is clinical work a busy practice rarely has time for. A licensed physician reviews the case, tells you candidly whether it has merit, and where it does writes a letter that names the exact step or criterion at issue, sets out the trial history with dates and doses, documents intolerance or contraindication where it exists, argues the clinical risk of destabilising a regimen you are doing well on, and cites the specialty-society guidelines and labeling that support the drug your physician chose.

Cove Health cannot guarantee results. What it puts on the record is a request argued in the plan's own terms, with each authority cited so the reviewer can check it. Guides to a related decision are on the step therapy page.

Cove Health provides advocacy services. Information on this site is general information, not legal or medical advice. Cove Health is not a law firm and does not provide legal representation, and submission of records does not guarantee a particular outcome.

Frequently asked questions

Step therapy denials for this category, answered.

Why did my plan deny a biologic my rheumatologist prescribed? +
Most often because of step therapy: the plan covers the biologic only after a less expensive drug has been tried and has not worked. Denials in this class also come from prior authorization criteria that ask for a documented diagnosis, disease-activity measures, or specific laboratory and screening results that the submitted paperwork did not include.
I already failed methotrexate years ago. Does that count? +
It usually can, if it is documented. Step rules are applied to the pharmacy claim, not to your history, so a trial that happened under a previous plan or a previous prescriber often has to be re-established from old records: fill histories, chart notes, and the visit where the outcome was recorded.
My plan wants me to switch to a biosimilar. Is that a denial? +
It is a formulary preference rather than a clinical finding. Plans routinely prefer one product in a class and require an exception for the others. Where there is a documented clinical reason the preferred product is not appropriate, that reason is what an exception request has to state and support.
Can I appeal if I am already stable on the drug and the plan stopped covering it? +
Yes. Continuity of an established, stable regimen is a recognised ground in many step therapy and exception policies, and it is argued with the record of how you have done on the current drug. What the policy allows depends on your plan and, for some plans, on state law.
Does a peer-to-peer call replace an appeal? +
No. A peer-to-peer is a brief call between your prescriber and the plan's reviewer, and it leaves little written trace. A cited written appeal puts the same argument on the record where it has to be answered, and the two can be used together.

Still have a question?

Keep reading

Other commonly denied medications

CGRP migraine injections denied: Aimovig, Emgality and AjovyPreventive migraine injectables are usually denied because a plan wants older preventives tried first, or because the headache diary the criteria ask for was never submitted. Here is how that appeal works.Step therapyRead the guide →JAK inhibitors denied: Rinvoq, Xeljanz and OlumiantJAK inhibitors usually sit behind a step requirement that asks for a biologic first, plus safety documentation. Here is what the criteria ask for and how an override request answers them.Step therapyRead the guide →Sleep medications denied: Belsomra, Quviviq and DayvigoInsomnia drugs are commonly gated behind older generics, sleep-study documentation or quantity limits. Here is what the criteria ask for and how an appeal answers them.Step therapyRead the guide →